Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 12—December 2021
Research Letter

Guillain-​Barré Syndrome Associated with COVID-19 Vaccination

Shih-Chieh Shao1, Chien-Ho Wang1, Kai-Cheng Chang, Ming-Jui Hung, Hui-Yu Chen, and Shu-Chen LiaoComments to Author 
Author affiliations: Keelung Chang Gung Memorial Hospital, Keelung, Taiwan (S.-C. Shao, C.-H. Wang, M.-J. Hung, S.-C. Liao); National Cheng Kung University College of Medicine, Tainan, Taiwan (S.-C. Shao, K-C, Chang); Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan (K.-C. Chang, H.-Y. Chen); Chang Gung University College of Medicine, Taoyuan (M.-J. Hung, S.-C. Liao)

Cite This Article


We conducted a multi-institutional study in Taiwan and a systematic review of the literature for reports of Guillain-​Barré syndrome after coronavirus disease vaccination. This condition, mostly the classic form and the acute inflammatory demyelinating polyneuropathy subtype, has been reported in 39 cases and has occurred within 2 weeks of vaccine administration.

Guillain-Barré syndrome (GBS), an immune-mediated polyradiculoneuropathy with a ≈5% mortality rate, has an incidence worldwide of 0.81–1.91 cases/100,000 person-years (1). GBS has been reported to be associated with coronavirus disease (COVID-19) vaccination, but a comprehensive summary regarding this rare adverse event is still lacking. To determine clinical features of GBS associated with COVID-19 vaccination, we conducted hospital-based investigations in Taiwan along with a systematic review of published case reports.

We analyzed electronic medical records data from Taiwan’s largest multi-institutional healthcare system, including 9 branches of Chang Gung Memorial Hospital (2), where healthcare workers received first-priority COVID-19 ChAdOx1-S vaccine (Oxford/AstraZeneca, starting March 22, 2021. We included healthcare workers vaccinated during March 22–May 31 and followed them for 30 days after vaccination. We identified GBS cases on the basis of code G610 from the International Classification of Disease, 10th Revision, Clinical Modification, or spontaneous adverse drug reaction reporting systems within the hospitals. Two authors (C.H.W. and S.C.L.) confirmed diagnosis and classification of GBS cases through chart reviews (3,4). This study was approved by the Institutional Review Board of Chang Gung Medical Foundation (approval no. 202101087B0).

To summarize clinical features of published cases from literature, we searched PubMed and Embase for reports posted through August 17, 2021, using relevant key terms such as “COVID-19,” “Guillain-​Barré syndrome,” and “vaccine” with suitable MeSH terms. Two independent reviewers (S.C.S., C.H.W.) performed the study selection and data extraction; a third-reviewer (S.C.L.) settled any differences between them. We excluded cases with coexisting COVID-19 or preexisting GBS. We included only publications with reports of clinical features related to GBS. We described basic characteristics, laboratory data, pathologic reports, treatment patterns, and prognosis of GBS cases associated with COVID-19 vaccination. The study protocol of this systematic review is published on PROSPERO (

We included 18,269 healthcare workers (mean age 40.6 years, range 18–87 years; 67.5% were women) who received ChAdOx1-S vaccine during the study period. After these 18,257 first-dose and 544 second-dose vaccinations, we identified 1 GBS case after a first dose of ChAdOx1-S vaccine in 1 of the hospitals participating in the study.


Systematic review of published literature in study of Guillain-​Barré syndrome associated with coronavirus vaccination, 2021. GBS, Guillain-​Barré syndrome.

Figure. Systematic review of published literature in study of Guillain-​Barré syndrome associated with coronavirus vaccination, 2021. GBS, Guillain-​Barré syndrome.

After a systematic review of published literature (Figure), we included 17 publications reporting an additional 38 cases of GBS related to COVID-19 vaccination (India, 10 cases; United Kingdom, 11 cases; Mexico, 7 cases; United States, 3 cases; France, 1 case; Italy, 3 cases; Malta, 1 case; Turkey, 1 case; and Qatar, 1 case) (Appendix Table). Including the case in Taiwan, these 39 cases occurred in persons with a mean age of 57.8 (range 20–86) years; 56.4% were male. Most of the reported case-patients received ChAdOx1-S (25/39), followed by BNT162b2 (12/39) (Pfizer-BioNTech,, Ad26.COV2.S (1/39) (Johnson & Johnson,, and CoronaVac (1/39) (Sinovac Biotech, The GBS rate after COVID-19 vaccination ranged from 1.8 to 53.2 cases/1 million doses. The initial symptoms of GBS included myalgia (12/39), paraparesis (5/39), quadriparesis (22/39), paresthesia (28/39), and facial palsy (23/39), and symptoms of dysautonomia also were observed during hospitalizations (3/39). The average time from vaccination to symptom onset was 11.3 days. A total of 34 case-patients received lumbar puncture; 30 had manifestations of albuminocytologic dissociation in the cerebrospinal fluid.

On the basis of the clinical diagnostic classification of GBS, we found that most case-patients had the classic form (22/39), followed by bilateral facial palsy with paresthesia (12/39), the paraparetic form (4/39), and GBS–Miller Fisher syndrome overlap variant (1/39). We defined all classic and paraparetic forms of GBS (26/26) as level 1 or 2 on the basis of the Brighton criteria (5). We identified the GBS subtype in 33/39 cases by electrophysiological examination; most reported case-patients had a diagnosis of acute inflammatory demyelinating polyneuropathy (23/33), followed by acute motor and sensory axonal neuropathy (4/33) and acute motor axonal neuropathy (3/33). For GBS management, 33 case-patients received intravenous immunoglobulin and 2 received plasmapheresis. One case-patient died; 9 case-patients required mechanical ventilation during hospitalization. The scores on the GBS disability scale (5) were only available for 30 cases; 12 scored >4 (i.e., indicating bedridden or chair-bound status) during follow-up or after discharge.

Similar to previous reviews on GBS associated with COVID-19, we found that both COVID-19 and COVID-19 vaccination mostly cause the classic form of GBS (under the clinical diagnosis classification) and the acute inflammatory demyelinating polyneuropathy subtype (based on electrodiagnostic features) within 2 weeks of infection or vaccination (68). However, the bilateral facial palsy with paresthesia variant and initial onset symptoms of facial diplegia were more frequently found in GBS case-patients after COVID-19 vaccination.

Case series and reports can indicate safety issues and outline clinical features of diseases, but they cannot establish robust causal relationships between COVID-19 vaccination and GBS. Despite the benefits (e.g., increase in the number of persons not susceptible to infection and decrease in severe outcomes after infection) of COVID-19 vaccination far outweighing the potentially severe adverse events after infection (9), our findings highlight the need for vigilance in patients with neurologic symptoms after COVID-19 vaccination and for postvaccination surveillance programs to assess causality of GBS.

Dr. Shao is a clinical pharmacist at Keelung Chang Gung Memorial Hospital. His research interests include the use of systematic review and meta-analysis to summarize current best evidence on clinical topics, specifically in regard to complications in COVID-19 patients.



We thank Cheng-Yang Hsieh and Wen-Mei Cheng for their insightful opinions on this study.



  1. Shahrizaila  N, Lehmann  HC, Kuwabara  S. Guillain-Barré syndrome. Lancet. 2021;397:121428. DOIPubMedGoogle Scholar
  2. Shao  SC, Chan  YY, Kao Yang  YH, Lin  SJ, Hung  MJ, Chien  RN, et al. The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019;28:593600. DOIPubMedGoogle Scholar
  3. Uncini  A, Vallat  JM, Jacobs  BC. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. 2020;91:110510. DOIPubMedGoogle Scholar
  4. Leonhard  SE, Mandarakas  MR, Gondim  FAA, Bateman  K, Ferreira  MLB, Cornblath  DR, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15:67183. DOIPubMedGoogle Scholar
  5. Fokke  C, van den Berg  B, Drenthen  J, Walgaard  C, van Doorn  PA, Jacobs  BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137:3343. DOIPubMedGoogle Scholar
  6. Koike  H, Chiba  A, Katsuno  M. Emerging infection, vaccination, and Guillain-Barré syndrome: a review. Neurol Ther. 2021. DOIPubMedGoogle Scholar
  7. Uncini  A, Vallat  JM, Jacobs  BC. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry. 2020;91:110510. DOIPubMedGoogle Scholar
  8. Abu-Rumeileh  S, Abdelhak  A, Foschi  M, Tumani  H, Otto  M. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021;268:113370. DOIPubMedGoogle Scholar
  9. Goodman  JL, Grabenstein  JD, Braun  MM. Answering key questions about COVID-19 vaccines. JAMA. 2020;324:20278. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid2712.211634

Original Publication Date: October 14, 2021

1These authors contributed equally to this article.

Table of Contents – Volume 27, Number 12—December 2021

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Address for correspondence to: Shu-Chen Liao, Department of Emergency Medicine, Keelung Chang Gung Memorial Hospital, 222 Maijin Rd, Keelung, Taiwan

Send To

10000 character(s) remaining.


Page created: October 06, 2021
Page updated: November 21, 2021
Page reviewed: November 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.